BACKGROUND: Hemorrhage is the leading cause of preventable trauma-related deaths, and histone deacetylase inhibitors (HDACI) such as valproic acid (VPA) can improve survival following lethal hemorrhage. HDACI acetylate proteins, and acetylation regulates many cellular functions. Here we have investigated the effects of VPA treatment on extracellular signal-regulated kinase 1/2 (ERK) activation, as ERK is well known to modulate cell death, gene expression, and inflammation. MATERIALS AND METHODS: Anesthetized Wistar-Kyoto rats were subjected to lethal (60%) blood loss, and then randomized (n = 5-6/group) to (1) VPA 300 mg/kg or (2) vehicle control. Survival was monitored for 24 h. A separate group of rats were subjected to sublethal (40%) hemorrhage and were treated with VPA or vehicle. Rats were sacrificed at 1, 4, and 20 h, and lung tissue was assessed for the degree of acetylation of histone 3, and activation (phosphorylation) of ERK. Sham animals served as normal controls. RESULTS: Sixty percent hemorrhage resulted in severe shock. Only 17% of the vehicle-treated animals survived (most died within 1 h), whereas 80% of the VPA-treated animals survived (P < 0.05). Hemorrhage resulted in a significant increase in phosphorylated ERK (activated form) compared with sham at the 1 and 4 h time points, but not at the 20 h time point. VPA treatment significantly attenuated these changes, while increasing histone protein acetylation. CONCLUSIONS: VPA treatment significantly improves survival following lethal hemorrhagic shock. Hemorrhage induces ERK activation, which is significantly attenuated by VPA treatment. This may represent one mechanism through which VPA promotes survival in otherwise lethal hemorrhagic shock. Copyright 2010 Elsevier Inc. All rights reserved.
BACKGROUND:Hemorrhage is the leading cause of preventable trauma-related deaths, and histone deacetylase inhibitors (HDACI) such as valproic acid (VPA) can improve survival following lethal hemorrhage. HDACI acetylate proteins, and acetylation regulates many cellular functions. Here we have investigated the effects of VPA treatment on extracellular signal-regulated kinase 1/2 (ERK) activation, as ERK is well known to modulate cell death, gene expression, and inflammation. MATERIALS AND METHODS: Anesthetized Wistar-Kyoto rats were subjected to lethal (60%) blood loss, and then randomized (n = 5-6/group) to (1) VPA 300 mg/kg or (2) vehicle control. Survival was monitored for 24 h. A separate group of rats were subjected to sublethal (40%) hemorrhage and were treated with VPA or vehicle. Rats were sacrificed at 1, 4, and 20 h, and lung tissue was assessed for the degree of acetylation of histone 3, and activation (phosphorylation) of ERK. Sham animals served as normal controls. RESULTS: Sixty percent hemorrhage resulted in severe shock. Only 17% of the vehicle-treated animals survived (most died within 1 h), whereas 80% of the VPA-treated animals survived (P < 0.05). Hemorrhage resulted in a significant increase in phosphorylated ERK (activated form) compared with sham at the 1 and 4 h time points, but not at the 20 h time point. VPA treatment significantly attenuated these changes, while increasing histone protein acetylation. CONCLUSIONS:VPA treatment significantly improves survival following lethal hemorrhagic shock. Hemorrhage induces ERK activation, which is significantly attenuated by VPA treatment. This may represent one mechanism through which VPA promotes survival in otherwise lethal hemorrhagic shock. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: S Namura; K Iihara; S Takami; I Nagata; H Kikuchi; K Matsushita; M A Moskowitz; J V Bonventre; A Alessandrini Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: Joy L Collins; Yoram Vodovotz; Christian Hierholzer; Raphael T Villavicencio; Shubing Liu; Sean Alber; David Gallo; Donna B Stolz; Simon C Watkins; Anthony Godfrey; William Gooding; Edward Kelly; Andrew B Peitzman; Timothy R Billiar Journal: Shock Date: 2003-02 Impact factor: 3.454
Authors: Yongqing Li; Baoling Liu; Simon T Dillon; Eugene Y Fukudome; Tareq Kheirbek; Elizabeth A Sailhamer; George Velmahos; Marc deMoya; Towia A Libermann; Hasan B Alam Journal: J Surg Res Date: 2009-05-13 Impact factor: 2.192
Authors: Ashley R Kochanek; Eugene Y Fukudome; Yongqing Li; Eleanor J Smith; Baoling Liu; George C Velmahos; Marc deMoya; David King; Hasan B Alam Journal: J Surg Res Date: 2011-07-05 Impact factor: 2.192
Authors: Panpan Chang; Michael Weykamp; Isabel S Dennahy; Aaron M Williams; Umar F Bhatti; Baoling Liu; Vahagn C Nikolian; Yongqing Li; Hasan B Alam Journal: J Trauma Acute Care Surg Date: 2018-05 Impact factor: 3.313
Authors: Nimesh S A Patel; Kiran K Nandra; Michael Brines; Massimo Collino; Ws Fred Wong; Amar Kapoor; Elisa Benetti; Fera Y Goh; Roberto Fantozzi; Anthony Cerami; Christoph Thiemermann Journal: Mol Med Date: 2011-05-13 Impact factor: 6.354
Authors: Nimesh S A Patel; Hannah L Kerr-Peterson; Michael Brines; Massimo Collino; Mara Rogazzo; Roberto Fantozzi; Elizabeth G Wood; Florence L Johnson; Muhammad M Yaqoob; Anthony Cerami; Christoph Thiemermann Journal: Mol Med Date: 2012-05-09 Impact factor: 6.354
Authors: Zhengcai Liu; Yongqing Li; Baoling Liu; Danielle K Deperalta; Ting Zhao; Wei Chong; Xiuzhen Duan; Peter Zhou; George C Velmahos; Hasan B Alam Journal: J Trauma Acute Care Surg Date: 2013-04 Impact factor: 3.313